Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.20
AKRX's Cash to Debt is ranked lower than
87% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. AKRX: 0.20 )
Ranked among companies with meaningful Cash to Debt only.
AKRX' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.2 Max: No Debt
Current: 0.2
Equity to Asset 0.41
AKRX's Equity to Asset is ranked lower than
79% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. AKRX: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
AKRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.52 Max: 0.91
Current: 0.41
0.1
0.91
Interest Coverage 7.05
AKRX's Interest Coverage is ranked lower than
77% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 98.90 vs. AKRX: 7.05 )
Ranked among companies with meaningful Interest Coverage only.
AKRX' s Interest Coverage Range Over the Past 10 Years
Min: 1.71  Med: 7.13 Max: No Debt
Current: 7.05
F-Score: 6
Z-Score: 3.31
M-Score: -1.96
WACC vs ROIC
10.13%
16.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 30.87
AKRX's Operating margin (%) is ranked higher than
92% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.87 vs. AKRX: 30.87 )
Ranked among companies with meaningful Operating margin (%) only.
AKRX' s Operating margin (%) Range Over the Past 10 Years
Min: -37.46  Med: 12 Max: 30.87
Current: 30.87
-37.46
30.87
Net-margin (%) 17.00
AKRX's Net-margin (%) is ranked higher than
83% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. AKRX: 17.00 )
Ranked among companies with meaningful Net-margin (%) only.
AKRX' s Net-margin (%) Range Over the Past 10 Years
Min: -36.24  Med: 8.16 Max: 31.41
Current: 17
-36.24
31.41
ROE (%) 28.97
AKRX's ROE (%) is ranked higher than
90% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.03 vs. AKRX: 28.97 )
Ranked among companies with meaningful ROE (%) only.
AKRX' s ROE (%) Range Over the Past 10 Years
Min: -50.57  Med: 12.1 Max: 35.12
Current: 28.97
-50.57
35.12
ROA (%) 9.22
AKRX's ROA (%) is ranked higher than
76% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. AKRX: 9.22 )
Ranked among companies with meaningful ROA (%) only.
AKRX' s ROA (%) Range Over the Past 10 Years
Min: -33.5  Med: 4.36 Max: 24.27
Current: 9.22
-33.5
24.27
ROC (Joel Greenblatt) (%) 81.27
AKRX's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.38 vs. AKRX: 81.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AKRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -48.35  Med: 39.16 Max: 81.27
Current: 81.27
-48.35
81.27
Revenue Growth (3Y)(%) 50.10
AKRX's Revenue Growth (3Y)(%) is ranked higher than
94% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. AKRX: 50.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AKRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.1  Med: 4.3 Max: 56.6
Current: 50.1
-37.1
56.6
EBITDA Growth (3Y)(%) 61.10
AKRX's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. AKRX: 61.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AKRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.1  Med: 45.6 Max: 149.9
Current: 61.1
-64.1
149.9
EPS Growth (3Y)(%) 56.20
AKRX's EPS Growth (3Y)(%) is ranked higher than
90% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. AKRX: 56.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AKRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.4  Med: 27.9 Max: 93.1
Current: 56.2
-50.4
93.1
» AKRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

AKRX Guru Trades in Q3 2015

Jim Simons 274,120 sh (New)
Mario Gabelli 29,500 sh (+27.71%)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
Murray Stahl 18,866 sh (-2.17%)
Columbia Wanger 3,316,265 sh (-3.11%)
Steven Cohen 374,100 sh (-22.87%)
» More
Q4 2015

AKRX Guru Trades in Q4 2015

Andreas Halvorsen 1,841,346 sh (New)
George Soros 20,100 sh (New)
John Paulson 2,879,138 sh (New)
Steven Cohen 427,865 sh (+14.37%)
Mario Gabelli 31,100 sh (+5.42%)
Jim Simons Sold Out
Murray Stahl 16,548 sh (-12.29%)
Columbia Wanger 2,735,646 sh (-17.51%)
» More
Q1 2016

AKRX Guru Trades in Q1 2016

John Paulson 9,318,600 sh (+223.66%)
Murray Stahl 27,192 sh (+64.32%)
Mario Gabelli 46,300 sh (+48.87%)
Andreas Halvorsen 2,081,398 sh (+13.04%)
George Soros Sold Out
Steven Cohen Sold Out
Columbia Wanger 2,096,707 sh (-23.36%)
» More
Q2 2016

AKRX Guru Trades in Q2 2016

Steven Cohen 120,600 sh (New)
George Soros 38,400 sh (New)
Paul Tudor Jones 30,765 sh (New)
Joel Greenblatt 403,835 sh (New)
Jim Simons 175,600 sh (New)
Andreas Halvorsen Sold Out
Columbia Wanger 2,076,628 sh (-0.96%)
John Paulson 9,012,900 sh (-3.28%)
Mario Gabelli 44,600 sh (-3.67%)
Murray Stahl 15,028 sh (-44.73%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:STDAF, NAS:HZNP, NYSE:CTLT, OTCPK:INVVY, NAS:MDCO, NAS:NBIX, NAS:RDUS, NYSE:DPLO, NAS:ENDP, NAS:IRWD, NAS:IPXL, NAS:OPK, NAS:INNL, OTCPK:HYPMY, NAS:PCRX, OTCPK:IPSEY, NAS:CPXX, NYSE:TARO, OTCPK:ORINY, NYSE:LCI » details
Traded in other countries:FDA.Germany,
Akorn Inc manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals.

Akorn Inc is a Louisiana corporation founded in 1971 in Abita Springs, Louisiana. The Company is a generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals and branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. It operates pharmaceutical manufacturing facilities in Decatur, Illinois and Somerset, New Jersey, and in Paonta Sahib, Himachal Pradesh, India. It also operates a Research and Development center in Vernon Hills, Illinois and a distribution warehouse in Gurnee, Illinois. Its two operating segments are Prescription Pharmaceuticals and Consumer Health. Its Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a variety of dosage forms including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals, nasal sprays and otics. Its Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. The Companys customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. The Company is competitors for hospital drugs & injectables segment include both generic and name brand companies such as Hospira, Inc., Teva Pharmaceutical Industries, Pfizer, Sagent Pharmaceuticals, Novartis, Fresenius-Kabi, Daiichi Sankyo, and Hikma. For ophthalmic segment its competitors include, Allergan Pharmaceuticals, Inc., Novartis, Valeant Pharmaceuticals International, Inc., Apotex and Sun Pharmaceuticals, among others.

Top Ranked Articles about Akorn Inc

John Paulson Increases Bet on Health Care for 7th Quarter Hedge fund manager increased sector for seventh consecutive quarter to more than half of long portfolio
As 13F filings rolled in this week, the most notable revelation of John Paulson (Trades, Portfolio)’s was his reduction of his SPDR Gold Trust (GLD) stake, a mainstay of his portfolio for years, at a significant loss. Paulson, the head of hedge fund Paulson & Co., in his next most prominent move increased his holding of health care stocks for the seventh consecutive quarter. The sector made up more than 57% of his long portfolio, compared to 48.3% the previous quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.20
AKRX's P/E(ttm) is ranked higher than
73% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.55 vs. AKRX: 18.20 )
Ranked among companies with meaningful P/E(ttm) only.
AKRX' s P/E(ttm) Range Over the Past 10 Years
Min: 12.14  Med: 37.34 Max: 495
Current: 18.2
12.14
495
Forward P/E 12.76
AKRX's Forward P/E is ranked higher than
72% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.89 vs. AKRX: 12.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.20
AKRX's PE(NRI) is ranked higher than
73% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.41 vs. AKRX: 18.20 )
Ranked among companies with meaningful PE(NRI) only.
AKRX' s PE(NRI) Range Over the Past 10 Years
Min: 12.14  Med: 37.34 Max: 495
Current: 18.2
12.14
495
Price/Owner Earnings (ttm) 45.51
AKRX's Price/Owner Earnings (ttm) is ranked lower than
60% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.58 vs. AKRX: 45.51 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AKRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.08  Med: 53.85 Max: 273.15
Current: 45.51
11.08
273.15
P/B 4.37
AKRX's P/B is ranked lower than
66% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.04 vs. AKRX: 4.37 )
Ranked among companies with meaningful P/B only.
AKRX' s P/B Range Over the Past 10 Years
Min: 1.42  Med: 6.58 Max: 41.45
Current: 4.37
1.42
41.45
P/S 3.15
AKRX's P/S is ranked lower than
54% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.78 vs. AKRX: 3.15 )
Ranked among companies with meaningful P/S only.
AKRX' s P/S Range Over the Past 10 Years
Min: 0.75  Med: 6.11 Max: 12.93
Current: 3.15
0.75
12.93
PFCF 32.75
AKRX's PFCF is ranked lower than
61% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.70 vs. AKRX: 32.75 )
Ranked among companies with meaningful PFCF only.
AKRX' s PFCF Range Over the Past 10 Years
Min: 10.51  Med: 91.76 Max: 2950
Current: 32.75
10.51
2950
POCF 22.36
AKRX's POCF is ranked lower than
62% of the 248 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. AKRX: 22.36 )
Ranked among companies with meaningful POCF only.
AKRX' s POCF Range Over the Past 10 Years
Min: 9.08  Med: 47.23 Max: 189.57
Current: 22.36
9.08
189.57
EV-to-EBIT 12.14
AKRX's EV-to-EBIT is ranked higher than
76% of the 524 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.32 vs. AKRX: 12.14 )
Ranked among companies with meaningful EV-to-EBIT only.
AKRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -4983.2  Med: 13.8 Max: 213.1
Current: 12.14
-4983.2
213.1
EV-to-EBITDA 9.65
AKRX's EV-to-EBITDA is ranked higher than
77% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.57 vs. AKRX: 9.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -506.9  Med: 17.9 Max: 2955.7
Current: 9.65
-506.9
2955.7
PEG 0.35
AKRX's PEG is ranked higher than
92% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. AKRX: 0.35 )
Ranked among companies with meaningful PEG only.
AKRX' s PEG Range Over the Past 10 Years
Min: 0.06  Med: 0.43 Max: 0.66
Current: 0.35
0.06
0.66
Shiller P/E 93.02
AKRX's Shiller P/E is ranked lower than
71% of the 154 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.01 vs. AKRX: 93.02 )
Ranked among companies with meaningful Shiller P/E only.
AKRX' s Shiller P/E Range Over the Past 10 Years
Min: 78.54  Med: 323.02 Max: 4455
Current: 93.02
78.54
4455
Current Ratio 4.28
AKRX's Current Ratio is ranked higher than
72% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. AKRX: 4.28 )
Ranked among companies with meaningful Current Ratio only.
AKRX' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.3 Max: 9.96
Current: 4.28
0.21
9.96
Quick Ratio 2.93
AKRX's Quick Ratio is ranked higher than
67% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AKRX: 2.93 )
Ranked among companies with meaningful Quick Ratio only.
AKRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.12 Max: 8.49
Current: 2.93
0.02
8.49
Days Inventory 158.19
AKRX's Days Inventory is ranked lower than
70% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. AKRX: 158.19 )
Ranked among companies with meaningful Days Inventory only.
AKRX' s Days Inventory Range Over the Past 10 Years
Min: 90.54  Med: 142.57 Max: 188.37
Current: 158.19
90.54
188.37
Days Sales Outstanding 68.91
AKRX's Days Sales Outstanding is ranked higher than
56% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.29 vs. AKRX: 68.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.49  Med: 51.71 Max: 123.33
Current: 68.91
24.49
123.33
Days Payable 42.64
AKRX's Days Payable is ranked lower than
76% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.16 vs. AKRX: 42.64 )
Ranked among companies with meaningful Days Payable only.
AKRX' s Days Payable Range Over the Past 10 Years
Min: 19.92  Med: 52.74 Max: 123.76
Current: 42.64
19.92
123.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.60
AKRX's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 424 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. AKRX: -7.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AKRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.1  Med: -3.4 Max: -0.9
Current: -7.6
-63.1
-0.9

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.34
AKRX's Price/Projected FCF is ranked higher than
52% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. AKRX: 2.34 )
Ranked among companies with meaningful Price/Projected FCF only.
AKRX' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.18  Med: 12.38 Max: 749
Current: 2.34
2.18
749
Price/Median PS Value 0.51
AKRX's Price/Median PS Value is ranked higher than
91% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. AKRX: 0.51 )
Ranked among companies with meaningful Price/Median PS Value only.
AKRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.41 Max: 1.98
Current: 0.51
0.04
1.98
Price/Peter Lynch Fair Value 0.73
AKRX's Price/Peter Lynch Fair Value is ranked higher than
86% of the 152 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.51 vs. AKRX: 0.73 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AKRX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.47  Med: 1.21 Max: 2.77
Current: 0.73
0.47
2.77
Earnings Yield (Greenblatt) (%) 8.22
AKRX's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. AKRX: 8.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AKRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 3.9 Max: 10
Current: 8.22
0.5
10
Forward Rate of Return (Yacktman) (%) 50.99
AKRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
95% of the 331 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.18 vs. AKRX: 50.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AKRX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.5  Med: -1.2 Max: 1017.9
Current: 50.99
-15.5
1017.9

More Statistics

Revenue (TTM) (Mil) $1,086
EPS (TTM) $ 1.49
Beta1.58
Short Percentage of Float10.50%
52-Week Range $17.57 - 41.96
Shares Outstanding (Mil)126.03

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,082 1,169 1,263
EPS ($) 2.15 2.35 2.59
EPS w/o NRI ($) 2.15 2.35 2.59
EPS Growth Rate
(3Y to 5Y Estimate)
10.86%
Dividends Per Share ($)
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Analysts Disagree Over Significance of Akorn, Inc’s Financial Errors Apr 28 2015 
Weekly CEO Sells Highlight: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic Packag Aug 09 2014 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL Sep 24 2012 
5 Healthcare Picks for 2012 Mar 21 2012 
Weekly CFO Sells Highlight: AN, CATM, AKRX, NNN, FTNT Aug 28 2011 
Akorn Inc. (AKRX) CFO Timothy A Dick buys 3,900 Shares Aug 16 2010 
Akorn Inc. Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
Akorn’s Robust Research and Development Pipeline: A Growth Driver Aug 29 2016
Analyst Recommendations for Akorn in 2016 Aug 29 2016
Akorn’s 2016 Valuation Multiples Compared to Peers Aug 29 2016
Akorn Relaunches Ofloxacin Otic Solution Aug 25 2016
AKORN INC Files SEC form 8-K, Regulation FD Disclosure Aug 25 2016
Akorn Relaunches Ofloxacin Otic Solution Aug 25 2016
Akorn to Present at Morgan Stanley Global Healthcare Conference Aug 24 2016
'Mad Money' Lightning Round: Take Nucor Over U.S. Steel Aug 24 2016
What Are Analysts Recommending for Teva Pharmaceutical in 2016? Aug 19 2016
Akorn Appoints Robert Monahan as Senior Vice President of Corporate Development Aug 18 2016
AKORN INC Files SEC form 8-K, Regulation FD Disclosure Aug 18 2016
Akorn Appoints Robert Monahan as Senior Vice President of Corporate Development Aug 18 2016
What Are Analysts’ Recommendations for Mylan and Its Peers? Aug 17 2016
AKORN INC Financials Aug 12 2016
Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : August 11, 2016 Aug 11 2016
ETF’s with exposure to Akorn, Inc. : August 9, 2016 Aug 09 2016
Akorn, Inc. :AKRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 Aug 08 2016
Akorn downgraded by Deutsche Bank Aug 05 2016
Akorn (AKRX) Stock Drops Despite Q2 Beat Aug 04 2016
Edited Transcript of AKRX earnings conference call or presentation 4-Aug-16 2:00pm GMT Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)